Home/Filings/4/0001104659-21-016806
4//SEC Filing

Sofinnova Venture Partners X, L.P. 4

Accession 0001104659-21-016806

CIK 0001641281other

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 6:04 PM ET

Size

18.2 KB

Accession

0001104659-21-016806

Insider Transaction Report

Form 4
Period: 2021-02-09
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,200,2282,304,437 total
  • Conversion

    Series C-2 Preferred Stock

    2021-02-091,200,2280 total
    Common Stock (1,200,228 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,104,2091,104,209 total
  • Purchase

    Common Stock

    2021-02-09$20.00/sh+450,000$9,000,0002,754,437 total
  • Conversion

    Series C-1 Preferred Stock

    2021-02-091,104,2090 total
    Common Stock (1,104,209 underlying)
Katabi Maha
10% Owner
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,200,2282,304,437 total
  • Conversion

    Series C-1 Preferred Stock

    2021-02-091,104,2090 total
    Common Stock (1,104,209 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,104,2091,104,209 total
  • Purchase

    Common Stock

    2021-02-09$20.00/sh+450,000$9,000,0002,754,437 total
  • Conversion

    Series C-2 Preferred Stock

    2021-02-091,200,2280 total
    Common Stock (1,200,228 underlying)
Transactions
  • Conversion

    Common Stock

    2021-02-09+1,200,2282,304,437 total
  • Conversion

    Series C-1 Preferred Stock

    2021-02-091,104,2090 total
    Common Stock (1,104,209 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,104,2091,104,209 total
  • Purchase

    Common Stock

    2021-02-09$20.00/sh+450,000$9,000,0002,754,437 total
  • Conversion

    Series C-2 Preferred Stock

    2021-02-091,200,2280 total
    Common Stock (1,200,228 underlying)
Transactions
  • Conversion

    Series C-2 Preferred Stock

    2021-02-091,200,2280 total
    Common Stock (1,200,228 underlying)
  • Purchase

    Common Stock

    2021-02-09$20.00/sh+450,000$9,000,0002,754,437 total
  • Conversion

    Series C-1 Preferred Stock

    2021-02-091,104,2090 total
    Common Stock (1,104,209 underlying)
  • Conversion

    Common Stock

    2021-02-09+1,104,2091,104,209 total
  • Conversion

    Common Stock

    2021-02-09+1,200,2282,304,437 total
Footnotes (3)
  • [F1]The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
  • [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
  • [F3]The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

Issuer

Bolt Biotherapeutics, Inc.

CIK 0001641281

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001680200

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 6:04 PM ET
Size
18.2 KB